MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia

Abstract

Acute myeloid leukemia (AML) requires refined risk stratification tools to drive decisions concerning effective therapeutic strategies. Here, genome-wide screening was carried out for identifying miRNA molecules capable of predicting treatment outcome in AML patients based on the TCGA dataset. We identified miR-340 as a prognostic factor for selecting treatment between chemotherapy and allogeneic transplantation (allo-HSCT). In multivariable analyses, low miR-340 expression independently predicted reduced OS (HR = 2.07, P = 0.004) and EFS (HR = 1.909, P = 0.01) independent of other well-known prognostic factors. Meanwhile, allo-HSCT overcome deleterious outcomes related to low miR-340. Cases administered allo-HSCT showed markedly improved OS (HR = 0.316, P < 0.0001) and EFS (HR = 0.391, P = 0.002) in comparison with those receiving chemotherapy in the low miR-340 group. Gene expression assessment revealed that elevated miR-340 amounts were negatively correlated with HOXA/HOXB cluster levels, as well as the amounts of the HOX cofactor MEIS1. Strikingly, in silico analysis pointing to HOXA10, HOXB2, and MEIS1 as miR-340 targets. The miR-340 expression may help identify cases requiring strategies for selecting the optimal therapeutic option between chemotherapy and allo-HCST. AML cases showing low miR-340 levels should be strongly considered for early allo-HSCT treatment.

Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p/Myc axis in acute myeloid leukemia

“…LncRNAs and miRNAs play crucial roles in regulating multiple cellular processes and have been reported as potential therapeutic targets in AML [17,18]. miRNAs, a class of evolutionarily conserved, endogenous non-coding RNAs of about 22 nucleotides, can post-transcriptionally regulate gene expression of target mRNAs, resulting in translational repression or target degradation [19].…”

LINC00662 promotes cell viability and metastasis in esophageal squamous cell carcinoma by sponging miR‐340‐5p and upregulating HOXB2

“…16 Moreover, HOXB2 has been demonstrated to be a target of miR-340 in acute myeloid leukemia. 17 However, the role of HOXB2 in ESCC has not been reported in previous studies.…”

Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker and therapeutic target for gastric cancer

“…Specifically, HOXB1 has been shown to be downregulated in gliomas and lung cancers, and its expression inhibits the apoptosis and promotes the proliferation of cancer cells (10,11). Additionally, HOXB2 has been shown to be upregulated in cervical cancer and pancreatic cancer (12,13), and was found to be the targets of multiple small RNAs in colorectal cancer (CRC), glioblastoma, and acute myeloid leukemia (14)(15)(16). HOXB3 has been shown to be a target of microRNA-10a (miR-10a) and regulated by retinoic acid receptor signaling pathway in pancreatic cancer metastasis (17).…”